Results of Operations and Financial Condition. On August 7, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18…

Entry into a Material Definitive Agreement. Underwriting Agreement On May 18, 2026, Rapid Micro Biosystems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Lake Street Capital Markets LLC, as representatives of the several underwriters named therein (the “Underwriters”) relating to an underwritten offering (the “Offering”) of (i) 3,581,000 shares (the “Shares”) of the Company’s Class A common stock, $0.01 par value pe…

Results of Operations and Financial Condition. On May 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 1…

Chief Operating Officer — Mr. John Wilson: Mr. John Wilson, the Chief Operating Officer, is departing to spend more time with his family.

Results of Operations and Financial Condition. On March 12, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

Results of Operations and Financial Condition. On January 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit…

Results of Operations and Financial Condition. On November 7, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of…

Results of Operations and Financial Condition. On August 12, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Secti…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. On August 8, 2025 (the “Closing Date”), Rapid Micro Biosystems, Inc. (the "Company") entered into a Loan and Security Agreement (the “LSA”) with the lenders party thereto (the “Lenders”) and Trinity Capital Inc., as administrative agent and collateral agent (the “Agent”). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $45.0 million avail…

Director — Jeffrey Schwartz: Mr. Schwartz resigned from the board of directors without a named successor.

Results of Operations and Financial Condition. On May 9, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 1…

Results of Operations and Financial Condition. On February 28, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed”…

Entry into a Material Definitive Agreement. Distribution and Collaboration Agreement On February 21, 2025, Rapid Micro Biosystems, Inc. (“we”, “us” or the “Company”) entered into a Distribution and Collaboration Agreement (the “Distribution Agreement”) with Millipore S.A.S., a subsidiary of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma (“MilliporeSigma”). Pursuant to the Distribution Agreement, we granted MilliporeSigma a global, co-…

Results of Operations and Financial Condition. On January 14, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit…

Director — David Hirsch, M.D., Ph.D.: Dr. Hirsch resigned from the board of directors without a named successor.

Results of Operations and Financial Condition. On November 1, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its third quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for pu…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 2, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for its Class A common stock, par value $0.01 per share (the “common stock”), had closed below $1.00 per share for the preceding thirty (30) consecutive business days (December 18…

Results of Operations and Financial Condition. On August 2, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its second quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes…

Results of Operations and Financial Condition. On May 3, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its first quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of…

Results of Operations and Financial Condition. On March 1, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 2, 2024, Rapid Micro Biosystems, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s Class A common stock, par value $0.01 (the “common stock”) had closed below $1.00 per share for the thirty (30) consecutive business days (…

Results of Operations and Financial Condition. On January 10, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit…

Results of Operations and Financial Condition. On November 3, 2023, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its third quarter ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for pu…